The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Moderna Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
36 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for mRESVIA respiratory syncytial virus F protein mRNA (nucleoside modified), 50 micrograms in 0.5 mL, suspension for injection, prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX JN.1 (SARS-CoV-2 JN.1 mRNA) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
Jan-2025Prescription medicine evaluationActive ingredient: SARS-CoV-2 spike NTD-RBD mRNA.
-
Cancellation by sponsorRequested by Moderna Australia Pty Ltd
-
Cancellation by sponsorRequested by Moderna Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - single-dose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial-single dose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial.